Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
4.010
+0.060 (1.52%)
At close: Nov 28, 2025, 1:00 PM EST
3.990
-0.020 (-0.50%)
After-hours: Nov 28, 2025, 4:59 PM EST
Esperion Therapeutics Employees
Esperion Therapeutics had 304 employees as of December 31, 2024. The number of employees increased by 64 or 26.67% compared to the previous year.
Employees
304
Change (1Y)
64
Growth (1Y)
26.67%
Revenue / Employee
$999,349
Profits / Employee
-$348,128
Market Cap
944.08M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 304 | 64 | 26.67% |
| Dec 31, 2023 | 240 | 41 | 20.60% |
| Dec 31, 2022 | 199 | -19 | -8.72% |
| Dec 31, 2021 | 218 | -261 | -54.49% |
| Dec 31, 2020 | 479 | 286 | 148.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ESPR News
- 8 days ago - Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 11 days ago - Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease - GlobeNewsWire
- 16 days ago - Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
- 17 days ago - Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript - Seeking Alpha
- 19 days ago - Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability - Seeking Alpha
- 22 days ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer - GlobeNewsWire